Next-Gen CGT Pipeline Powered by the FAST CGT Platform
Regulatory T cell Therapies
Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppressants for autoimmune disease treatment and transplant rejection prevention.
Product Name | Adaption | Preclinical | Phase1 | Phase2 | Phase3 |
---|---|---|---|---|---|
TregCelTM | Solid organ transplantation (kidney) | ||||
Engineered Treg | Autoimmune diseases |
Engineered MSC Therapies
Utilizing the FAST CGT platform enhance therapeutic efficacy, durability, and precision of MSC therapies for treating inflammatory and ischemic diseases.
Product Name | Adaption | Preclinical | Phase1 | Phase2 | Phase3 | |
---|---|---|---|---|---|---|
ChondrochymalTM | Knee osteoarthritis | |||||
Biochymal | Critical limb ischemia |